Kao Li-Ting, Yang Tsung-Ying, Hung Wei-Chun, Yang Wei-Te, He Pu, Chen Bo-Xuan, Wang Yu-Chi, Chen Shiou-Sheng, Lai Yu-Wei, Wang Hsian-Yu, Tseng Sung-Pin
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Orthopaedic Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Antibiotics (Basel). 2024 Sep 23;13(9):906. doi: 10.3390/antibiotics13090906.
Recently, the high proportion of methicillin-resistant infections worldwide has highlighted the urgent need for novel antibiotics to combat this crisis. The recent progress in computational techniques for use in health and medicine, especially artificial intelligence (AI), has created new and potential approaches to combat antibiotic-resistant bacteria, such as repurposing existing drugs, optimizing current agents, and designing novel compounds. Halicin was previously used as a diabetic medication, acting as a c-Jun N-terminal protein kinase (JNK) inhibitor, and has recently demonstrated unexpected antibacterial activity. Although previous efforts have highlighted halicin's potential as a promising antibiotic, evidence regarding its effectiveness against clinical strains remains limited, with insufficient proof of its clinical applicability. In this study, we sought to investigate the antibacterial activity of halicin against MRSA clinical strains to validate its clinical applicability, and a model infected by MRSA was employed to evaluate the in vivo effect of halicin against MRSA. Our findings revealed the antibacterial activity of halicin against methicillin-resistant clinical strains with MICs ranging from 2 to 4 µg/mL. Our study is also the first work to evaluate the in vivo effect of halicin against using a model, supporting its further development as an antibiotic.
最近，耐甲氧西林感染在全球范围内的高比例凸显了对抗这一危机的新型抗生素的迫切需求。用于健康和医学领域的计算技术，特别是人工智能（AI）的最新进展，为对抗抗生素耐药细菌创造了新的潜在方法，如重新利用现有药物、优化现有药物以及设计新型化合物。卤霉素以前用作糖尿病药物，作为一种c-Jun氨基末端蛋白激酶（JNK）抑制剂，最近已证明具有意外的抗菌活性。尽管此前的研究强调了卤霉素作为一种有前景的抗生素的潜力，但关于其对临床菌株有效性的证据仍然有限，其临床适用性的证据不足。在本研究中，我们试图研究卤霉素对耐甲氧西林金黄色葡萄球菌临床菌株的抗菌活性，以验证其临床适用性，并采用耐甲氧西林金黄色葡萄球菌感染模型来评估卤霉素对耐甲氧西林金黄色葡萄球菌的体内作用。我们的研究结果显示卤霉素对耐甲氧西林临床菌株具有抗菌活性，其最低抑菌浓度范围为2至4µg/mL。我们的研究也是第一项使用感染模型评估卤霉素体内作用的工作，支持其作为一种抗生素的进一步开发。
